Loading patent…
AssigneeMallinckrodt Pharmaceuticals Ireland Limited
InventorsKhurram Jamil, Stephen Chris Pappas, Peter Teuber
Estimating the term…
The principles and embodiments of the present disclosure relate to methods for using terlipressin to treat a patient having impaired renal function associated with liver disease. A method of improving kidney function in an adult patient with hepatorenal syndrome with rapid reduction in kidney function may include determining the patient’s acute-on-chronic liver failure (ACLF) grade and baseline serum creatinine level; obtaining a baseline oxygenation saturation (SpO2) of the patient; administering a dose of terlipressin acetate to the patient by intravenous (IV) injection; and monitoring the patient’s oxygenation saturation with pulse oximetry.
A method of improving kidney function in an adult patient with hepatorenal syndrome with rapid reduction in kidney function comprising administering a 1 mg IV injection of terlipressin acetate to a patient in need thereof, wherein the administering provides a derived typical population PK parameter of clearance for terlipressin of 27.4 L/hr and a derived typical population PK parameter of clearance for lysine-vasopressin of 318 L/hr.
A method of improving kidney function in an adult patient with hepatorenal syndrome with rapid reduction in kidney function comprising administering a 1 mg IV injection of terlipressin acetate to a patient in need thereof, wherein the administering provides a Cmax of 70.5 ng/mL at steady state, a AUC24h of 123 ng×hr/mL, and a Cave of 14.2 ng/mL.
A method of improving kidney function in an adult patient with hepatorenal syndrome with rapid reduction in kidney function comprising:
Dependencies are inferred from the claim text.